Who is sponsoring NCT05641454?

NCT05641454 is sponsored by University of Exeter.

What drugs are being tested in NCT05641454?

Interventions in NCT05641454: ElevATP supplement, Placebo.

What condition does NCT05641454 study?

NCT05641454 studies Caffeine and Endurance Performance.

Is NCT05641454 still recruiting?

NCT05641454 is currently completed. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT05641454: APEX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of a Peat and Apple Extract on Muscle ATP and Exercise Performance

Completed NA Last updated 22 March 2023

What this trial tests

NA trial testing ElevATP supplement in Caffeine and Endurance Performance in 10 participants. Completed in 15 February 2023.

Timeline

17 October 2022

Primary endpoint
15 February 2023

15 February 2023

Quick facts

Lead sponsor	University of Exeter
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	10
Start date	17 October 2022
Primary completion	15 February 2023
Estimated completion	15 February 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

ElevATP supplement
Placebo

Conditions studied

Caffeine and Endurance Performance — all drugs for Caffeine and Endurance Performance →

Sponsor

University of Exeter

Who can join

Adults 18 to 40, male only, with Caffeine and Endurance Performance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to test the hypothesis that a combined peat and apple extract will increase blood and muscle ATP, which will increase cycling performance

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Exeter trials

Trials by the same sponsor.

NCT07457437 — Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment · NA · recruiting
NCT06478121 — Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) · recruiting
NCT06965699 — The Effect of a Plant-based, Protein-dense Sauce on Essential Amino Acid Concentrations and Gut Fullness in Older Adults · NA · recruiting
NCT06846294 — Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether · NA · not yet recruiting
NCT06852547 — The Effect of Ingesting a Novel Algae Protein Source on Rested and Exercised Muscle Protein Synthesis Rates in Older Adu · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05641454 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Exeter
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing